Loading clinical trials...
Loading clinical trials...
Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis
Conditions
Interventions
Obeticholic Acid 5 MG
Obeticholic Acid 10 MG
+1 more
Locations
1
United States
Intercept Pharmaceuticals, Inc
San Diego, California, United States
Start Date
March 28, 2022
Primary Completion Date
June 1, 2023
Completion Date
July 1, 2023
Last Updated
October 10, 2023
NCT07304843
NCT07449793
NCT06755541
NCT05749822
NCT05751967
NCT07296458
Lead Sponsor
Intercept Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions